Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Globalisation and blood safety

Identifieur interne : 000212 ( PascalFrancis/Checkpoint ); précédent : 000211; suivant : 000213

Globalisation and blood safety

Auteurs : Albert Farrugia [Australie]

Source :

RBID : Pascal:09-0291026

Descripteurs français

English descriptors

Abstract

Globalisation may be viewed as the growing interdependence of countries worldwide through the increasing volume and variety of cross-border transactions in goods and services, and also through the more rapid and widespread diffusion of technology. Globalisation is not just an economic phenomenon, although it is frequently described as such, but includes commerce, disease and travel, and immigration, and as such it affects blood safety and supply in various ways. The relatively short travel times offered by modern aviation can result in the rapid spread of blood-borne pathogens before measures to counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus included an asymptomatic viraemia. This risk can be amplified by ecological factors which effect the spread of these pathogens once they are transferred to a naïve ecosystem, as happened with West Nile Virus (WNV) in North America. The rationalization and contraction of the plasma products industry may be viewed as one aspect of globalisation imposed by the remorseless inevitability of the market; the effect of this development on the safety and supply of products has yet to be seen, but the oversight and assurance of a shrinking number of players will present particular challenges. Similarly, the monopolization of technology, through patent enforcement which puts access beyond the reach of developing countries, can have an effect on blood safety. The challenges presented to blood safety by globalisation are heightening the tensions between the traditional focus on the product safety - zero risk paradigm and the need to view the delivery of safe blood as an integrated process. As an illustration of this tension, donor deferral measures imposed by globalisation-induced risks such as vCJD and WNV have resulted in the loss of the safest and most committed portion of the blood donor population in many Western countries, leading to an increased risk to safety and supply. It is only through an appreciation of the basic needs of transfusion medicine, including the enunciation of appropriate principles to manage, rather than eliminate, risks, that the challenges imposed by globalisation may be overcome.


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:09-0291026

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Globalisation and blood safety</title>
<author>
<name sortKey="Farrugia, Albert" sort="Farrugia, Albert" uniqKey="Farrugia A" first="Albert" last="Farrugia">Albert Farrugia</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Blood and Tissues Unit, Australian Therapeutic Goods Administration, P.O. Box 100 Woden</s1>
<s2>ACT 2606</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>ACT 2606</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">09-0291026</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0291026 INIST</idno>
<idno type="RBID">Pascal:09-0291026</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000207</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000781</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000212</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000212</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Globalisation and blood safety</title>
<author>
<name sortKey="Farrugia, Albert" sort="Farrugia, Albert" uniqKey="Farrugia A" first="Albert" last="Farrugia">Albert Farrugia</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Blood and Tissues Unit, Australian Therapeutic Goods Administration, P.O. Box 100 Woden</s1>
<s2>ACT 2606</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>ACT 2606</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Blood reviews</title>
<title level="j" type="abbreviated">Blood rev.</title>
<idno type="ISSN">0268-960X</idno>
<imprint>
<date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Blood reviews</title>
<title level="j" type="abbreviated">Blood rev.</title>
<idno type="ISSN">0268-960X</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Blood product</term>
<term>Globalization</term>
<term>Harmlessness</term>
<term>Hematology</term>
<term>Human</term>
<term>Transfusion</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Constituant sang</term>
<term>Mondialisation</term>
<term>Innocuité</term>
<term>Transfusion</term>
<term>Homme</term>
<term>Hématologie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Mondialisation</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Globalisation may be viewed as the growing interdependence of countries worldwide through the increasing volume and variety of cross-border transactions in goods and services, and also through the more rapid and widespread diffusion of technology. Globalisation is not just an economic phenomenon, although it is frequently described as such, but includes commerce, disease and travel, and immigration, and as such it affects blood safety and supply in various ways. The relatively short travel times offered by modern aviation can result in the rapid spread of blood-borne pathogens before measures to counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus included an asymptomatic viraemia. This risk can be amplified by ecological factors which effect the spread of these pathogens once they are transferred to a naïve ecosystem, as happened with West Nile Virus (WNV) in North America. The rationalization and contraction of the plasma products industry may be viewed as one aspect of globalisation imposed by the remorseless inevitability of the market; the effect of this development on the safety and supply of products has yet to be seen, but the oversight and assurance of a shrinking number of players will present particular challenges. Similarly, the monopolization of technology, through patent enforcement which puts access beyond the reach of developing countries, can have an effect on blood safety. The challenges presented to blood safety by globalisation are heightening the tensions between the traditional focus on the product safety - zero risk paradigm and the need to view the delivery of safe blood as an integrated process. As an illustration of this tension, donor deferral measures imposed by globalisation-induced risks such as vCJD and WNV have resulted in the loss of the safest and most committed portion of the blood donor population in many Western countries, leading to an increased risk to safety and supply. It is only through an appreciation of the basic needs of transfusion medicine, including the enunciation of appropriate principles to manage, rather than eliminate, risks, that the challenges imposed by globalisation may be overcome.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0268-960X</s0>
</fA01>
<fA03 i2="1">
<s0>Blood rev.</s0>
</fA03>
<fA05>
<s2>23</s2>
</fA05>
<fA06>
<s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Globalisation and blood safety</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>FARRUGIA (Albert)</s1>
</fA11>
<fA14 i1="01">
<s1>Blood and Tissues Unit, Australian Therapeutic Goods Administration, P.O. Box 100 Woden</s1>
<s2>ACT 2606</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20>
<s1>123-128</s1>
</fA20>
<fA21>
<s1>2009</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>22071</s2>
<s5>354000186253930040</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>09-0291026</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Blood reviews</s0>
</fA64>
<fA66 i1="01">
<s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Globalisation may be viewed as the growing interdependence of countries worldwide through the increasing volume and variety of cross-border transactions in goods and services, and also through the more rapid and widespread diffusion of technology. Globalisation is not just an economic phenomenon, although it is frequently described as such, but includes commerce, disease and travel, and immigration, and as such it affects blood safety and supply in various ways. The relatively short travel times offered by modern aviation can result in the rapid spread of blood-borne pathogens before measures to counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus included an asymptomatic viraemia. This risk can be amplified by ecological factors which effect the spread of these pathogens once they are transferred to a naïve ecosystem, as happened with West Nile Virus (WNV) in North America. The rationalization and contraction of the plasma products industry may be viewed as one aspect of globalisation imposed by the remorseless inevitability of the market; the effect of this development on the safety and supply of products has yet to be seen, but the oversight and assurance of a shrinking number of players will present particular challenges. Similarly, the monopolization of technology, through patent enforcement which puts access beyond the reach of developing countries, can have an effect on blood safety. The challenges presented to blood safety by globalisation are heightening the tensions between the traditional focus on the product safety - zero risk paradigm and the need to view the delivery of safe blood as an integrated process. As an illustration of this tension, donor deferral measures imposed by globalisation-induced risks such as vCJD and WNV have resulted in the loss of the safest and most committed portion of the blood donor population in many Western countries, leading to an increased risk to safety and supply. It is only through an appreciation of the basic needs of transfusion medicine, including the enunciation of appropriate principles to manage, rather than eliminate, risks, that the challenges imposed by globalisation may be overcome.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B19</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B27D01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Constituant sang</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Blood product</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Constituyente sanguíneo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Mondialisation</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Globalization</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Globalización</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Innocuité</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Harmlessness</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Inocuidad</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Transfusion</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Transfusion</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Transfusión</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Homme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Human</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Hématologie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Hematology</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Hematología</s0>
<s5>10</s5>
</fC03>
<fN21>
<s1>215</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations>
<list>
<country>
<li>Australie</li>
</country>
</list>
<tree>
<country name="Australie">
<noRegion>
<name sortKey="Farrugia, Albert" sort="Farrugia, Albert" uniqKey="Farrugia A" first="Albert" last="Farrugia">Albert Farrugia</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000212 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000212 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:09-0291026
   |texte=   Globalisation and blood safety
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021